Literature DB >> 7188663

Antagonism of Org NC 45 neuromuscular blockade by neostigmine, pyridostigmine, and 4-aminopyridine.

L H Booij, F van der Pol, J F Crul, R D Miller.   

Abstract

The antagonism of Org NC 45 neuromuscular blockade by neostigmine, pyridostigmine, 4-aminopyridine, and their combinations was studied in the in vivo rat sciatic nerve anterior tibialis preparation using the constant infusion of Org NC 45 technique. The ED50 (dose of drug which produced a 50% antagonism) of neostigmine, pyridostigmine, and 4-aminopyridine were 14.5, 75, and 466 micrograms/kg, respectively. The addition of 100 microgram/kg of 4-aminopyridine, which produced no antagonism by itself, decreased neostigmine ED50 to 9.8 micrograms/kg. The addition of 200 micrograms/kg of 4-aminopyridine, which produced a 14.8% antagonism by itself, decreased the ED50 of pyridostigmine to 17.5 micrograms/kg. We concluded that neostigmine, pyridostigmine, and 4-aminopyridine effectively antagonize an Org NC 45 neuromuscular blockade. Neostigmine and pyridostigmine interact with 4-aminopyridine in a synergistic manner. The doses of antagonists were very similar to those required to antagonize a pancuronium neuromuscular blockade.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7188663

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  3 in total

Review 1.  Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 2.  Org-NC45: a new steroidal non-depolarizing muscle relaxant.

Authors:  L H Booij; T B Vree; J E Crul
Journal:  Pharm Weekbl Sci       Date:  1982-02-19

3.  Antagonism of d-tubocurarine-induced neuromuscular blockade with a mixture of 4-aminopyridine and neostigmine in man.

Authors:  K Wirtavuori; M Salmenperä; T Tammisto
Journal:  Can Anaesth Soc J       Date:  1984-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.